FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____ to ____
DELAWARE 04-2743260 -------- ---------- (State of incorporation) (I.R.S. Employer No.) 33 CHERRY HILL DRIVE DANVERS, MASSACHUSETTS 01923 ---------------------------- |
(Address of principal executive offices, including zip code)
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) or the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes [X] No [_]
As of September 30, 1995, there were 5,513,833 shares outstanding of the registrant's Common Stock, $.01 par value, and 1,428,000 shares outstanding of the registrant's Class A Common Stock, $.01 par value.
ABIOMED, INC. AND SUBSIDIARIES
Page No. -------- Part I - Financial Information: Item 1. Financial Statements Consolidated Balance Sheets September 30, 1995 and March 31, 1995 3-4 Consolidated Statements of Operations Three and Six Months Ended September 30, 1995 and September 30, 1994 5 Consolidated Statements of Cash Flows Six Months Ended September 30, 1995 and September 30, 1994 6 Notes to Consolidated Financial Statements 7-9 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 10-13 Part II - Other Information 14-15 Signatures 16 |
ABIOMED, INC. AND SUBSIDIARIES
PART 1. FINANCIAL INFORMATION
ITEM 1: FINANCIAL STATEMENTS
September 30, 1995 March 31, 1995 ------------------- ------------------- (unaudited) (audited) Current Assets: Cash and cash equivalents (Note 6) $333,775 $614,091 Short-term investments (Note 6) 9,483,593 3,876,943 Accounts receivable, net 2,340,771 1,775,734 Inventories (Note 3) 1,253,351 1,409,280 Prepaid expense and other current asset 239,854 53,830 ------------------- ------------------- Total current assets 13,651,344 7,729,878 ------------------- ------------------- Investments (Note 6): Long-term marketable securities 662,536 6,533,490 ------------------- ------------------- Property and equipment, at cost Machinery and equipment 2,254,268 2,189,139 Furniture and fixtures 129,267 122,934 Leasehold improvements 308,178 279,181 ------------------- ------------------- 2,691,713 2,591,254 Less: Accumulated depreciation and amortization 2,218,449 2,124,234 473,264 467,020 ------------------- ------------------- Other Assets: Investment in Abiomed Limited Partnership, net (Note 7) 698,462 - ------------------- ------------------- $15,485,606 $14,730,388 =================== =================== |
The accompanying notes are an integral part of these consolidated financial statements.
ABIOMED, INC. AND SUBSIDIARIES
PART 1. FINANCIAL INFORMATION
ITEM 1: FINANCIAL STATEMENTS (continued)
September 30, 1995 March 31, 1995 (unaudited) (audited) ------------------ ----------------- Current Liabilities: Accounts payable $702,335 $198,280 Accrued expenses 1,229,556 1,227,379 ------------------ ----------------- Total current liabilities 1,931,891 1,425,659 ------------------ ----------------- Stockholders' Investment (Note 4): Class B Preferred Stock, $.01 par value- Authorized 1,000,000 shares Issued and outstanding-none - - Common Stock, $.01 par value- Authorized 25,000,000 shares at September 30, 1995 Issued and Outstanding-5,513,833 shares at September 30, 1995 and 4,885,852 shares at March 31, 1995 55,138 48,859 Class A Common Stock $.01 par value Authorized - 2,346,000 shares Issued and Outstanding - 1,428,000 shares at September 30, 1995 and 2,040,000 shares at March 31, 1995 14,280 20,400 Additional paid-in capital 36,593,088 36,476,770 Accumulated deficit (23,108,791) (23,241,300) ------------------ ----------------- Total stockholders' investment 13,553,715 13,304,729 ------------------ ----------------- $15,485,606 $14,730,388 ================== ================= |
The accompanying notes are an integral part of these consolidated financial statements.
ABIOMED, INC. AND SUBSIDIARIES
PART 1. FINANCIAL INFORMATION
ITEM 1: FINANCIAL STATEMENTS (continued)
Six Months Ended Three Months Ended ---------------- ------------------ September 30, 1995 September 30, 1994 September 30, 1995 September 30, 1994 ------------------- ------------------- ------------------- ------------------- Revenues: Products and services $4,394,792 $2,638,608 $2,270,351 $1,339,629 Contracts 1,455,297 1,162,106 836,248 602,382 ------------------- ------------------- ------------------- ------------------- 5,850,089 3,800,714 3,106,599 1,942,011 ------------------- ------------------- ------------------- ------------------- Costs and expenses: Cost of products and services 1,822,769 1,056,759 907,876 518,058 Research and development (including costs related to contracts) 1,519,037 1,141,038 860,178 549,447 Selling, general and administrative 2,631,499 2,125,741 1,414,585 1,078,286 ------------------- ------------------- ------------------- ------------------- 5,973,305 4,323,538 3,182,639 2,145,791 ------------------- ------------------- ------------------- ------------------- Net income (loss) from operations (123,216) (522,824) (76,040) (203,780) Interest and other income 255,725 216,238 124,488 113,243 ------------------- ------------------- ------------------- ------------------- Net income (loss) $ 132,509 ($306,586) $ 48,448 ($90,537) =================== =================== =================== =================== Net income (loss) per common share share (Note 5): $.02 ($.05) $.01 ($.01) =================== =================== =================== =================== Weighted average number of common and dilutive common equivalent shares outstanding 6,967,191 6,474,016 6,972,429 6,474,183 =================== =================== =================== =================== |
The accompanying notes are an integral part of these consolidated financial statements.
ABIOMED, INC. AND SUBSIDIARIES
PART 1. FINANCIAL INFORMATION
ITEM 1: FINANCIAL STATEMENTS (continued)
Six Months Ended ---------------- September 30, 1995 September 30, 1994 ------------------ ------------------ CASH FLOWS FROM OPERATING ACTIVITIES: Net income (loss) $132,509 ($306,586) Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities- Depreciation and amortization 165,751 151,009 Non cash transactions related to Abiomed Limited Partnership - (119,794) Changes in assets and liabilities- Accounts receivable (565,037) 422,875 Inventories 155,929 (268,886) Prepaid expenses and other current assets (186,024) (87,715) Accounts payable 504,055 77,498 Accrued expenses 2,177 (361,789) ------------------ ----------------- Net cash (used in) provided by operating activities 209,360 (493,388) ------------------ ----------------- CASH FLOWS FROM INVESTING ACTIVITIES: (Purchases) sales of investments, net 264,303 396,238 Purchases and improvements of property and equipment (100,458) (35,494) Purchases of limited partner units (Note 7) (770,000) - ------------------ ----------------- Net cash (used in) provided by investing activities (606,155) 360,744 ------------------ ----------------- CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from exercise of stock options and stock issued under employee stock purchase plan 116,479 8,858 ------------------ ----------------- Net cash provided by financing activities 116,479 8,858 ------------------ ----------------- NET DECREASE IN CASH AND EQUIVALENTS, EXCLUDING INVESTMENTS (280,316) (123,786) CASH AND CASH EQUIVALENTS, EXCLUDING INVEST- MENTS, AT BEGINNING OF PERIOD 614,091 480,058 ------------------ ----------------- CASH AND CASH EQUIVALENTS , EXCLUDING INVEST- MENTS, AT END OF PERIOD $ 333,775 $ 356,272 ================== ================= |
The accompanying notes are an integral part of these consolidated financial statements.
ABIOMED, INC. AND SUBSIDIARIES
PART 1. FINANCIAL INFORMATION (continued)
ITEM 1: FINANCIAL STATEMENTS (continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
The unaudited consolidated financial statements of ABIOMED, Inc. (the Company), presented herein have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by generally accepted accounting principles. These statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company's latest audited financial statements, which are contained in the Company's Form 10-K for the year ended March 31, 1995, which was filed with the Securities and Exchange Commission. In the opinion of management, the accompanying consolidated financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. The results of operations for the six months ended September 30, 1995 may not be indicative of the results that may be expected for the full fiscal year.
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, ABIOMED Cardiovascular, Inc., ABIOMED R&D Inc., ABIODENT, Inc., Abiomed Research and Development, Inc., ABD Holding Company, Inc., and the accounts of its majority-owned subsidiary Abiomed Limited Partnership (see Note 7). All significant intercompany accounts and transactions have been eliminated in consolidation.
Inventories include raw materials, work-in-process, and finished goods and are priced at the lower of cost (first-in, first-out) or market and consist of the following:
September 30, March 31, 1995 1995 ------------- ------------ Raw Materials $ 457,702 $ 339,686 Work-in-Process 485,534 412,956 Finished goods 310,115 656,638 ---------- ---------- TOTAL $1,253,351 $1,409,280 ========== ========== |
Finished goods and work-in-process inventories consist of direct material, labor, and overhead.
ABIOMED, INC. AND SUBSIDIARIES
PART 1. FINANCIAL INFORMATION (continued)
ITEM 1: FINANCIAL STATEMENTS (continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited, continued)
On August 9, 1995, the Stockholders of the Company voted to increase the number of authorized shares of Common Stock from 10,000,000 to 25,000,000 shares.
Effective August 10, 1995, in accordance with the rights for the Class A Common Stock, 612,000 shares of Class A Common Stock $.01 par value were converted into an equal number of shares of the Company's $.01 par value Common Stock.
During the second quarter of fiscal 1996, options to purchase 13,500 shares of Common Stock were granted with an exercise price of $7.50 per share. Options to purchase 2,000 shares were canceled during the quarter. Options to purchase 15,450 shares were exercised in the second quarter at exercise prices ranging from $5.75 to $8.50 per share. A total of 531 shares of Common Stock were issued under the Company's Employee Stock Purchase Plan.
Net income (loss) per common share has been computed by dividing the net income (loss) by the weighted average number of common and common equivalent shares outstanding during the period. Common equivalent shares, such as stock options, have not been included in the per share calculation where the effect of their inclusion would be antidilutive. No common equivalent shares are considered dilutive in periods, such as the three and six month periods ended September 30, 1994, in which a loss is reported because all such common equivalent shares are antidilutive.
The Company classifies any marketable security with a maturity date of 90 days or less at the time of acquisition to be a cash equivalent. Securities, including marketable securities, with original maturities of greater than 90 days are classified as investments. Such investments are classified as long-term investments when their maturities are greater than one year from the balance sheet date. The company reports investments at cost plus accrued interest.
Abiomed Limited Partnership (the Partnership) was formed in March 1985 and provided initial funding for the design and development of two of the Company's products, the BVS and SupraCor (the Products). Today, the Partnership is inactive except for certain royalty rights, described below, on the Company's sales of the Products.
ABIOMED, INC. AND SUBSIDIARIES
PART 1. FINANCIAL INFORMATION (continued)
ITEM 1: FINANCIAL STATEMENTS (continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited, continued)
The Partnership consists of a sole general partner, which is the Company's wholly owned subsidiary, Abiomed Research and Development, Inc.; a special limited partner, which is the Company's wholly owned subsidiary ABIOMED Cardiovascular, Inc. (Cardiovascular); and one hundred thirty-five limited partner units. As of March 31, 1995 the Company held a 10.9% interest in the Partnership comprised of 1.0% by the general partner and 9.9% by the special limited partner while each of the limited partner units were owned by third party investor limited partners. The limited partner units aggregate to hold an 89.1% interest in the Partnership.
In May 1995, the Company made an offer to purchase each of the one hundred thirty-five limited partner units for $10,000 each. As of September 30, 1995 seventy-seven limited partner units had been tendered to the Company under this offer. The Company paid $770,000 with respect to these tenders through the six months ended September 30, 1995. Combined with the Company's initial 10.9% ownership, the Company now owns 61.7% of the Partnership. The Company's purchase of these limited partner units has been treated as a long-term asset and is being amortized over 5 years.
In March 1995, the Company satisfied all of its remaining fixed obligations to the Partnership. Commencing April 1, 1995 and ending August 3, 2000, the Company owes a royalty to the Partnership of 5.5% of certain revenues from the Products made during the period. Because the Company owns 61.7% of the Partnership, the net royalty to the Company is approximately 2.1%. This royalty formula is subject to certain maximum amounts and to certain additional adjustments in the event that the Company sells the technology.
ABIOMED, INC. AND SUBSIDIARIES
PART 1. FINANCIAL INFORMATION (continued)
ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Net income and income per share for the three months ended September 30, 1995 were approximately $49,000 and $.01 per share, respectively. These earnings compare to a net loss and loss per share of approximately $91,000 and $.01 per share, respectively, in the same period of the previous year.
Net income and income per share for the six months ended September 30, 1995 were approximately $133,000 and $.02 per share, respectively. These earnings compare to a loss of approximately $307,000 and $.05 per share in the same period of the previous year.
Product and service revenues were approximately $2,270,000, 69% higher than product and service revenues of approximately $1,340,000 in the same period of the previous year. These results primarily reflect increased units sales to new customers and increased units sales of the disposable cardiovascular product to the expanded installed customer base. Revenues from dental products, though growing, represented less than 10% of total revenues for the three months ended September 30, 1995. More than 90% of total product and service revenues were derived from domestic sources.
Revenues from Research and Development (R&D) contracts and grants for this quarter were approximately $836,000, 39% higher than total revenues of approximately $602,000 reported in the same quarter of the previous year. This increase primarily reflects timing of scheduled activities under existing contracts and grants. All such government contracts contain provisions making them terminable at the convenience of the government.
Product sales for the first six months of fiscal 1996 were $4,395,000 compared with $2,639,000 for the same period of the previous year, an increase of 67%. This growth primarily reflects increased units sales to new customers and increased units sales of the disposable
ABIOMED, INC. AND SUBSIDIARIES
PART 1. FINANCIAL INFORMATION (continued)
ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
cardiovascular product to the expanded installed customer base. Revenues from dental products continued to grow, however, represented less than 10% of total revenue for the six month period.
Revenues from Research and Development (R&D) contacts and grants for the six months ended September 30, 1995 were approximately $1,455,000, 25% higher than in the same period of the prior year. The increase primarily reflects the timing of scheduled activities under existing contracts and grants. All government grants and contracts contain provisions making them terminable at the convenience of the government.
Cost of products sold as a percentage of product sales (40%) was relatively unchanged from the same quarter of the previous year (39%) while increasing in total cost by approximately $390,000. These increased costs reflect higher product revenue levels attained in the current year's quarter.
Total research and development costs increased during the second fiscal quarter of 1996 to approximately $860,000, a 56% increase over research and development costs of approximately $550,000 incurred during the same fiscal period last year. The increase primarily reflects the timing of scheduled expenditures under contracts and grants.
Selling, general and administrative expenses for the three months ended September 30, 1995 increased to $1,415,000, 31% higher than selling, general and administrative expenses in the same fiscal quarter of the previous year. This increase primarily reflects increased sales and marketing expenses, particularly increased personnel and sales commissions, related to the increase in product and service revenues.
ABIOMED, INC. AND SUBSIDIARIES
PART 1. FINANCIAL INFORMATION (continued)
ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
30, 1994 (40%) while increasing in total cost by approximately $766,000. These increased costs primarily reflect higher product revenue levels.
Total research and development costs increased to approximately $1,519,000 for the six months ended September 30, 1995. This represents a 33% increase over the $1,141,000 reported for the same period in the previous fiscal year. The increase primarily reflects the timing of scheduled expenditures under contracts and grants.
Selling, general and administrative expenses for the six months ended September 30, 1995 increased to approximately $2,632,000, 24% higher than selling, general and administrative expenses in six month period ended September 30, 1994. This increase primarily reflects increased sales and marketing expenses, particularly increased personnel and sales commissions, related to the increase in product and service revenues.
Interest and other income increased to approximately $125,000 in the second quarter of 1996 compared with approximately $113,000 in the corresponding quarter of the prior year primarily due to a higher level of cash and investments.
For the six months ended September 30, 1995, interest and other income was approximately $256,000 compared to $216,000 for the six months ended September 30, 1994. This increase was primarily due to a higher level of cash and investments.
As of September 30, 1995, the Company's balance sheet included $10,480,000 in cash and investments, a decrease of approximately $545,000 from March 31, 1995. This decrease reflects $770,000 in cash used to purchase limited partner units of the Abiomed Limited Partnership net of approximately $225,000 in cash generated from operations and other activities. The September 30, 1995 balance includes approximately $334,000 in cash, $9,484,000 in short-term investments and $663,000 in investments with various maturities, the latest of which is October 1996. The Company also has a $3,000,000 line of credit from a bank which expires on December 1, 1995, and which was entirely available at September 30, 1995.
Net cash provided by operating activities included net income and depreciation and amortization expenses of approximately $298,000, an increase in accounts payable of $504,000
ABIOMED, INC. AND SUBSIDIARIES
PART 1. FINANCIAL INFORMATION (continued)
ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
and a decrease in inventories of approximately $156,000. These sources of cash were partially offset by an increase in accounts receivable of $565,000 and an increase of prepaid and other current assets of approximately $186,000. The increase in accounts receivable is attributable to increased credit sales and longer collection periods for certain accounts. The decrease in inventory was primarily attributable to a decrease in finished goods inventory due to increased product sales.
Net cash used in investing activities included $770,000 of purchases of limited partner units of Abiomed Limited Partnership (the Partnership) and approximately $100,000 of purchases and improvements of property and equipment which were partially offset by approximately $264,000 of net purchases and maturities of investments. As set forth in Note 7 of the financial statements included in this report, the Company had offered to purchase units of the investor limited partner's interests in the Partnership at a purchase price of $10,000 per unit. As of September 30, 1995 the Company had acquired and paid for seventy-seven (77) units of the Partnership.
Private and government proposals for significant health care reform are
expected to continue to affect healthcare expenditures in the United States as
well as internationally where the company sells or plans to sell its products.
The Company cannot assess at this time the potential impact that healthcare
trends may have on future results because of uncertainties surrounding any
unforseeable changes.
***
ABIOMED, INC. AND SUBSIDIARIES
PART II. OTHER INFORMATION
None
None
None
At the Company's annual meeting of shareholders held on August 9, 1995, the stockholders approved the following:
a) Elected six persons to serve as directors as follows:
Votes Director Votes For Withheld -------- --------- ------------- Dr. David Lederman (Class I) 4,234,980 140,443 Dr. Gerald W. Austen (Class III) 4,234,980 140,443 Paul Fireman (Class III) 4,229,549 145,874 John F. O'Brien (Class II) 4,234,980 140,443 Henri A. Termeer (Class II) 4,234,480 140,943 Desmond H. O'Connell, Jr. (Class I) 4,338,080 37,343 |
b) A proposal to amend the Company's certificate of incorporation to provide for the classification of the Board of Directors into three classes of directors with staggered terms of office. The proposal received 1,306,723 votes for and 622,185 against. There were 32,889 abstentions and 2,413,626 non-voting.
c) A proposal to amend the Company's certificate of incorporation regarding the consideration of all relevant factors in connection with certain business combinations. The proposal received 1,383,063 votes for and 594,965 against. There were 47,168 abstentions and 2,350,227 non- voting.
ABIOMED, INC. AND SUBSIDIARIES
PART II. OTHER INFORMATION
d) A proposal to amend the Company's certificate of incorporation to increase the number of shares of the Company's Common Stock authorized thereunder from 10,000,000 to 25,000,000 shares. The proposal received 3,626,244 votes for and 623,689 against. There were 30,100 abstentions and 95,380 non-voting.
e) A proposal to amend the Company's 1992 Combination Stock Option Plan to increase the number of shares that may be issued under that plan. The proposal received 1,274,114 votes for and 660,475 against. There were 27,558 abstentions and 2,413,276 non-voting.
f) A proposal to amend the Company's 1989 Non-Qualified Stock. Option Plan for Non-Employee Directors to increase the number of shares that may be issued under that plan. The proposal received 1,702,116 votes for and 288,878 against. There were 35,902 abstentions and 2,348,527 non-voting.
g) A proposal to act upon any matter incidental to the foregoing purpose and any other matter which may properly come before the Annual Meeting or any adjourned session thereof. There were no such matters acted upon during the Annual Meeting.
a) None
3.2 By-laws of ABIOMED, Inc., amended
10.1 ABIOMED, Inc. 1989 Non-Qualified Stock Option Plan for Non-Employee Directors, as amended
ABIOMED, INC AND SUBSIDIARIES
PART II, OTHER INFORMATION
10.2 ABIOMED, Inc. 1992 Combination Stock Option Plan, as amended
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ABIOMED, Inc.
Date: October 26 , 1995 /s/ ------------------------------- David M. Lederman CEO and President Date: October 26 , 1995 /s/ ------------------------------- John F. Thero Vice President Finance and Administration |
CERTIFICATE OF AMENDMENT
OF
CERTIFICATE OF INCORPORATION
ABIOMED, Inc.
ABIOMED, Inc., a corporation organized and existing under the laws of the State of Delaware (the "Corporation"), pursuant to Section 242 of the Delaware General Corporation Law, hereby certifies as follows:
1. The Board of Directors of the Corporation, at a meeting duly held on June 15, 1995, at which a quorum was present and acting throughout and in accordance with the provisions of Section 242 of the Delaware General Corporation Law, approved the following amendments to the Corporation's Certificate of Incorporation:
i. To increase the number of authorized shares of Common Stock, $.01 par value, from 10,000,000 to 25,000,000 shares.
ii. Paragraphs (c), (d) and (g) of Section 4.2.2 of Article 4 shall be amended to read in their entirety as follows:
(c) Any director elected by the holders of Common Stock voting as a separate class under paragraph (b) above may only be removed for cause by the holders of the Common Stock voting as a separate class. The remaining directors may be removed only for cause by the stockholders voting in accordance with paragraph (a).
(d) So long as there is any Class A Common Stock outstanding, any vacancy in the office of a director electable by the holders of Common Stock voting as a separate class may be filled by a vote of such holders voting as a separate class, and in the absence of such a stockholder vote, such vacancy may be filled by the remaining directors elected by the Common Stock voting as a separate class, and in the absence of any directors so elected, by all the remaining directors. So long as there is any Class A Common Stock outstanding, any vacancy in the office of a director electable by the holders of both classes of common stock voting as a single class shall be filled by the remaining directors elected by both classes, and in the absence of any directors so elected, by the holders of both classes of common stock voting as a single class. At such time as there is no longer any Class A Common Stock outstanding, any vacancy in the office of director shall be filled by the remaining directors, and in the absence of any directors, by the stockholders. Unless the conditions set forth in paragraph (f) exist in respect of the next annual meeting of stockholders, the Board of Directors may be enlarged by the Board of Directors only to the extent that twenty-five percent (25%) of the enlarged Board of Directors consists of directors either (i) elected by the holders of the Common Stock or (ii) appointed by directors elected by the holders of Common Stock voting as a separate class.
(g) This Certificate of Incorporation may be amended to change the powers, preferences, relative voting power or special rights of the shares of the Common Stock or the Class A Common Stock so as to affect either class adversely relative to the other, but any proposal to do so shall require the approval of a
majority of the votes entitled to be cast by the holders of the class adversely affected by the proposed amendment, voting separately as a class, in addition to the approval of a majority of the votes entitled to be cast by the holders of the Common Stock and the Class A Common Stock voting together as a single class as hereinbefore provided. In addition, this Section 4.2.2 shall not be amended, altered or repealed except by the affirmative vote of eighty percent (80%) of the votes entitled to be cast by the stockholders voting in accordance with paragraph (a).
iii. Article 13 shall be added to read in its entirety as follows:
(a) The number of directors of the corporation shall be the number, not less than 3 nor more than 12, fixed from time to time by the Board of Directors. The Board of Directors may be enlarged only by vote of a majority of the directors then in office.
(b) Commencing at the annual meeting of the stockholders in 1995, the directors shall be divided into three classes, designated Class I, Class II and Class III. Each class shall consist, as nearly as may be possible, of one third of the number of directors constituting the entire Board of Directors. At the annual meeting of the stockholders held in 1995, Class I directors shall be elected for a one year term, Class I directors shall be elected for a two year term, and Class III directors shall be elected for a three year term, and in each case until their successors are duly elected and qualified. Commencing in 1996, at each annual meeting of the stockholders successors to the class of directors whose terms expire at that annual meeting of stockholders shall be elected by stockholders for a three year term and until their successors are duly elected and qualified. If the number of directors constituting the entire Board of Directors shall be changed as provided in paragraph (a) of this Article 13, the increase or decrease shall be apportioned among the classes so as to maintain the number of directors in each class as nearly equal as possible.
(c) Any director elected to fill a vacancy resulting from an increase in any class or from the removal from office, death, disability, resignation or disqualification of a director or other cause shall hold office for the remaining term of the class to which such director is elected. No decrease in the size of the Board of Directors shall have the effect of removing or shortening the term of any incumbent director.
(d) Whenever the holders of any series of Preferred Stock issued pursuant to the provisions of Part 4.4 of Article 4 of this certificate of incorporation shall have the right, voting as a separate class, to elect directors, the election, term of office, filling of vacancies and other terms of such directorships shall be governed by the terms of this certificate of incorporation applicable to such series or by the resolution or resolutions of the Board of Directors providing for such series, as the case may be, and such directorships shall not be divided into classes or otherwise subject to this Article 13 unless expressly so provided therein.
(e) This Article 13 shall not be amended, altered or repealed except
by the affirmative vote of eighty percent (80%) of the votes
entitled to be cast by stockholders voting in accordance with
Section 4.2.2(a) of Article 4.
iv. Article 14 shall be added to read in its entirety as follows:
The Board of Directors of the corporation, when evaluating any offer of another party to (i) purchase or exchange any securities or property for any outstanding equity securities of the corporation, (ii) merge or consolidate the corporation with another corporation, or (iii) purchase or otherwise acquire all or substantially all of the properties and assets of the corporation, shall, in connection with the exercise of its judgment in determining what is in the best interests of the corporation and its stockholders, give due consideration to all relevant factors, including without limitation: (a) not only the price or other consideration being offered in relation to the then current market price of the corporation's outstanding shares of capital stock, but also the Board of Directors' estimate of the future value of the corporation as an independent going concern and the unrealized value of its property and assets; (b) the financial and managerial resources and future prospects of the other party; and (c) the possible social, legal, environmental and economic effects of the transaction on the business of the corporation and its subsidiaries and on the employees, customers, suppliers and creditors of the corporation and its subsidiaries and the effects on the communities in which the corporation's facilities are located. In evaluating any such offer on the basis of the foregoing factors, the directors shall be deemed to be performing their duly authorized duties and acting in good faith and in the best interests of the corporation within the meaning of Section 145 of the General Corporation Law of Delaware, as it may be amended from time to time.
2. The foregoing amendments to the Certificate of Incorporation were duly adopted by the stockholders at a meeting duly held, at which a quorum was present and acting throughout and in accordance with the provisions of Section 242 of the General Corporation Law of Delaware, on August 9, 1995.
IN WITNESS WHEREOF, ABIOMED, Inc. has caused this Certificate of Amendment of its Certificate of Incorporation to be signed by David M. Lederman, its President, and attested to by Donald E. Paulson, its Secretary, this 25th day of October, 1995.
ABIOMED, Inc.
By: /s/ David M. Lederman ------------------------------- David M. Lederman, President ATTEST: By: /s/ Donald E. Paulson ------------------------------- Donald E. Paulson, Secretary |
BY-LAWS
of
ABIOMED, Inc.
A Delaware Corporation
Adopted: June 4, 1987
Amended: July 2, 1990 and
June 15, 1995
/s/ Donald E. Paulson --------------------------- Secretary |
Page ---- ARTICLE I. - STOCKHOLDERS......................................................1 Section 1.1. Annual Meeting...................................................1 SECTION 1.2. SPECIAL MEETINGS.................................................1 Section 1.3. Notice of Meeting................................................1 Section 1.4. Quorum...........................................................2 Section 1.5. Voting and Proxies...............................................2 Section 1.6. Action at Meeting................................................2 Section 1.7. Action Without Meeting...........................................2 Section 1.8. Voting of Shares of Certain Holders..............................2 Section 1.9. Stockholder Lists................................................3 ARTICLE II. - BOARD OF DIRECTORS...............................................3 Section 2.1. Powers...........................................................3 Section 2.2. Number of Directors; Qualifications..............................4 Section 2.3. Nomination of Directors..........................................4 Section 2.4 Election of Directors............................................4 Section 2.5. Vacancies; Reduction of the Board................................4 Section 2.6. Enlargement of the Board.........................................4 Section 2.7. Tenure and Resignation...........................................5 Section 2.8. Removal..........................................................5 Section 2.9. Meetings.........................................................5 Section 2.10. Notice of Meeting...............................................5 Section 2.11. Agenda..........................................................5 Section 2.12. Quorum..........................................................6 Section 2.13. Action at Meeting...............................................6 Section 2.14. Action Without Meeting..........................................6 Section 2.15. Committees......................................................6 ARTICLE III. - OFFICERS........................................................6 Section 3.1. Enumeration......................................................6 Section 3.2. Election.........................................................7 Section 3.3. Qualification....................................................7 Section 3.4. Tenure...........................................................7 Section 3.5. Removal..........................................................7 Section 3.6. Resignation......................................................7 Section 3.7. Vacancies........................................................7 Section 3.8. Chairman of the Board............................................7 Section 3.9. President........................................................7 Section 3.10. Executive Vice-President; Vice-President(s).....................8 Section 3.11. Treasurer and Assistant Treasurers..............................8 Section 3.12. Secretary and Assistant Secretaries.............................8 Section 3.13. Other Powers and Duties.........................................8 |
ARTICLE IV. - CAPITAL STOCK....................................................9 Section 4.1. Stock Certificates...............................................9 Section 4.2. Transfer of Shares...............................................9 Section 4.3. Record Holders...................................................9 Section 4.4. Record Date......................................................9 Section 4.5. Transfer Agent and Registrar for Shares of Corporation..........10 Section 4.6. Loss of Certificates............................................10 Section 4.7. Restrictions on Transfer........................................11 Section 4.8. Multiple Classes of Stock.......................................11 ARTICLE V. - DIVIDENDS........................................................11 Section 5.1. Declaration of Dividends........................................11 Section 5.2. Reserves........................................................11 ARTICLE VI. - POWERS OF OFFICERS TO CONTRACT WITH THE CORPORATION.............12 ARTICLE VII. - INDEMNIFICATION................................................12 Section 7.1. Definitions.....................................................12 Section 7.2. Right to Indemnification in General.............................14 Section 7.3. Proceedings Other Than Proceedings by or in the Right of the Corporation...................................................14 Section 7.4. Proceedings by or in the Right of the Corporation...............14 Section 7.5. Indemnification of a Party Who is Wholly or Partly Successful...15 Section 7.6. Indemnification for Expenses of a Witness.......................15 Section 7.7. Advancement of Expenses.........................................15 Section 7.8. Notification and Defense of Claim...............................16 Section 7.9. Method of Determination.........................................17 Section 7.10. Presumptions and Effect of Certain Proceedings.................17 Section 7.11. Non-Exclusivity................................................18 Section 7.12. Insurance......................................................18 Section 7.13. No Duplicative Payment.........................................18 Section 7.14. Severability...................................................18 ARTICLE VIII. - MISCELLANEOUS PROVISIONS......................................19 Section 8.1. Certificate of Incorporation....................................19 Section 8.2. Fiscal Year.....................................................19 Section 8.3. Corporate Seal..................................................19 Section 8.4. Execution of Instruments........................................19 Section 8.5. Voting of Securities............................................19 Section 8.6. Evidence of Authority...........................................19 Section 8.7. Corporate Records...............................................19 Section 8.8. Charitable Contributions........................................20 ARTICLE IX. - AMENDMENTS......................................................20 Section 9.1. Amendment by Stockholders.......................................20 Section 9.2. Amendment by Board of Directors.................................20 |
BY-LAWS
OF
(A Delaware Corporation)
The requirement of notice to any stockholder may be waived by a written waiver of notice, executed before or after the meeting by the stockholder or his attorney thereunto duly authorized, and filed with the records of the meeting, or if communication with such stockholder is unlawful, or by attendance at the meeting without protesting prior thereto or at its commencement the lack of notice. A waiver of notice of any regular or special meeting of the stockholders need not specify the purposes of the meeting.
If a meeting is adjourned to another time or place, notice need not be given of the adjourned meeting if the time and place are announced at the meeting at which the adjournment is taken, except that if the adjournment is for more than thirty days, or if after the adjournment a new record date is fixed for the adjourned meeting, notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.
Shares of stock of the corporation standing in the name of a deceased person, a minor ward or an incompetent person, may be voted by his administrator, executor, court-appointed guardian or conservator without a transfer of such shares into the name of such administrator, executor, court appointed guardian or conservator. Shares of capital stock of the corporation standing in the name of a trustee may be voted by him.
Shares of stock of the corporation standing in the name of a receiver may be voted by such receiver, and shares held by or under the control of a receiver may be voted by such receiver without the transfer thereof into his name if authority so to do be contained in an appropriate order of the court by which such receiver was appointed.
A stockholder whose shares are pledged shall be entitled to vote such shares until the shares have been transferred into the name of the pledgee, and thereafter the pledgee shall be entitled to vote the shares so transferred.
Shares of its own stock belonging to this corporation shall not be voted, directly or indirectly, at any meeting and shall not be counted in determining the total number of outstanding shares at any given time, but shares of its own stock held by the corporation in a fiduciary capacity may be voted and shall be counted in determining the total number of outstanding shares.
consideration and upon such terms and conditions as they shall determine, including the granting of options, warrants or conversion or other rights to stock.
(a) Nominations for the election of directors may be made by the board of directors or by any stockholder entitled to vote for the election of directors. Nominations by stockholders shall be made by notice in writing, delivered or mailed by first class United States mail, postage prepaid, to the secretary of the corporation not less than 45 days nor more than 60 days prior to any meeting of the stockholders called for the election of directors.
(b) Each notice under subsection (a) shall set forth (i) the name, age, business address and, if known, residence address of each nominee proposed in such notice, (ii) the principal occupation or employment of each such nominee, and (iii) the number of shares of stock of the corporation which are beneficially owned by each such nominee.
(c) The chairman of the meeting of stockholders may, if the facts warrant, determine and declare to the meeting that a nomination was not made in accordance with the foregoing procedure, and if he should so determine, he shall so declare to the meeting and the defective nomination shall be disregarded.
Assistant treasurers, if any, shall have such powers and perform such duties as the board of directors may from time to time determine.
Assistant secretaries, if any, shall have such powers and perform such duties as the board of directors may from time to time designate.
If an officer, transfer agent or registrar who has signed, or whose facsimile signature has been placed on, a certificate shall have ceased to be such before the certificate is issued, it may be issued by the corporation with the same effect as if he were such officer, transfer agent or registrar at the time of its issue.
It shall be the duty of each stockholder to notify the corporation of his post office address.
of any other lawful action, the board of directors may fix, in advance, a record date, which shall not be more than sixty days prior to any other action. In such case only stockholders of record on such record date shall be so entitled notwithstanding any transfer of stock on the books of the corporation after the record date.
If no record date is fixed: (i) the record date for determining stockholders entitled to receive notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held; (ii) the record date for determining stockholders entitled to express consent to corporate action in writing without a meeting, when no prior action by the board of directors is necessary, shall be the day on which the first written consent is expressed; and (iii) the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the board of directors adopts the resolution relating thereto.
Any and all of the directors and officers of the corporation, notwithstanding their official relations to it, may enter into and perform any contract or agreement of any nature between the corporation and themselves, or any and all of the individuals from time to time constituting the board of directors of the corporation, or any firm or corporation in which any such director may be interested, directly or indirectly, whether such individual, firm or corporation thus contracting with the corporation shall thereby derive personal or corporate profits or benefits or otherwise; provided, that (i) the material facts of such interest are disclosed or are known to the board of directors or committee thereof which authorizes such contract or agreement; (ii) if the material facts as to such person's relationship or interest are disclosed or are known to the stockholders entitled to vote thereon, and the contract is specifically approved in good faith by a vote or the stockholders; or (iii) the contract or agreement is fair as to the corporation as of the time it is authorized, approved or ratified by the board of directors, a committee thereof, or the stockholders. Any director of the corporation who is interested in any transaction as aforesaid may nevertheless be counted in determining the existence of a quorum at any meeting of the board of directors which shall authorize or ratify any such transaction. This Article shall not be construed to invalidate any contract or other transaction which would otherwise be valid under the common or statutory law applicable thereto.
(a) "Code of Conduct" means the corporation's Code of Conduct for Directors, Officers and Employees as in effect from time to time.
(b) "Corporate Status" describes the status of a person who is or was a director, officer, employee, agent, trustee or fiduciary of the Corporation or of any other corporation, partnership, joint venture, trust, employee benefit plan or other Enterprise which such person is or was serving at the express written request of the corporation.
(c) "Court" means the Court of Chancery of the State of Delaware, the court in which the Proceeding in respect of which indemnification is sought by a Covered Person shall have been brought or is pending, or another court having subject jurisdiction and personal jurisdiction over the parties.
(d) "Covered Person" means a person who is a present or former director or officer of the corporation and shall include such person's legal representatives, heirs, executors and administrators.
(e) "Disinterested Director" means a director of the corporation who is not and was not a party to the Proceeding in respect of which indemnification is sought by a Covered Person.
(f) "Enterprise" shall mean the corporation and any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise of which a Covered Person is or was serving at the express written request of the corporation as a director, officer, employee, agent, trustee or fiduciary.
(g) "Expenses" shall include, without limitation, all reasonable attorneys' fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating or being or preparing to be a witness in a Proceeding.
(h) "Good Faith" shall mean a Covered Person having acted in good faith and in a manner such Covered Person reasonably believed to be in or not opposed to the best interests of the corporation or, in the case of an Enterprise which is an employee benefit plan, the best interests of the participants or beneficiaries of said plan, as the case may be, and, with respect to any Proceeding which is criminal in nature, having had no reasonable cause to believe such Covered Person's conduct was unlawful.
(i) "Independent Counsel" means a law firm, or a member of a law firm, that is experienced in matters of corporation law and may include law firms or members thereof that are regularly retained by the corporation but not any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term "Independent Counsel" shall not include any person who, under the standards of professional conduct then prevailing and applicable to such counsel, would have a conflict of interest in representing either the corporation or Covered Person in an action to determine Covered Person's rights under this Article.
(j) "Proceeding" includes any action, suit, arbitration, alternate dispute resolution mechanism, investigation (including any internal corporate investigation), administrative hearing or any other actual, threatened or completed proceeding whether civil, criminal, administrative or investigative, other than one initiated by the Covered Person. For purposes of the foregoing sentence, a "Proceeding" shall not be deemed to have been initiated by the Covered Person where such Covered Person seeks to enforce such Covered Person's rights under this Article.
(a) Each Covered Person shall be entitled to the rights of indemnification provided in this Section 7.4 if, by reason of such Covered Person's Corporate Status, such Covered Person is, or is threatened to be made, a party to or is otherwise involved in any Proceeding brought by or in the right of the corporation to procure a judgment in its favor. Such Covered Person shall be indemnified against Expenses, judgments, penalties, and amounts paid in settlement, actually and reasonably incurred by such Covered Person or on such Covered Person's behalf in connection with such Proceeding if such Covered Person acted in Good
Faith. Notwithstanding the foregoing, no such indemnification shall be made in respect of any claim, issue or matter in such Proceeding as to which such Covered Person shall have been adjudged to be liable to the corporation if applicable law prohibits such indemnification; provided, however, that, if applicable law so permits, indemnification shall nevertheless be made by the corporation in such event if and only to the extent that the Court which is considering the matter shall determine.
(b) Notwithstanding any provision to the contrary in this Section, if
the board of directors, Independent Counsel or the stockholders, as the case may
be, making the determination with respect to indemnification as provided under
Section 7.9 hereof, or the Court considering the matter determines that the act
or omission which forms the basis for the claim which is the subject of the
Proceeding violated the corporation's Code of Conduct then in effect, then,
notwithstanding that fact, the corporation may, to the extent authorized by the
board of directors, indemnify such Covered Person against all Expenses,
judgments, penalties and amounts paid in settlement, actually and reasonably
incurred by such Covered Person or on such Covered Person's behalf in connection
with such proceeding if such Covered Person acted in Good Faith.
Covered Person in connection with any Proceeding, within twenty (20) days after the receipt by the corporation of a statement or statements from such Covered Person requesting such advance or advances, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by the Covered Person and shall include or be preceded or accompanied by an undertaking by or on behalf of the Covered Person to repay any Expenses if it shall ultimately be determined that such Covered Person is not entitled to be indemnified against such Expenses. Any advance and undertakings to repay pursuant to this Section 7.7 shall be unsecured and interest free. Advancement of Expenses pursuant to this Section 7.7 shall not require approval of the board of directors or the stockholders of the corporation, or of any other person or body. The Secretary of the corporation shall promptly advise the Board in writing of the request for advancement of Expenses, of the amount and other details of the advance and of the undertaking to make repayment pursuant to this Section 7.7.
(a) The corporation will be entitled to participate in the defense at its own expense.
(b) Except as otherwise provided below, the corporation jointly with
any other indemnifying party similarly notified will be entitled to assume the
defense with counsel reasonably satisfactory to the Covered Person. After notice
from the corporation to the Covered Person of its election to assume the defense
of a suit, the corporation will not be liable to the Covered Person under this
Article for any legal or other expenses subsequently incurred by the Covered
Person in connection with the defense of the Proceeding other than reasonable
costs of investigation or as otherwise provided below. The Covered Person shall
have the right to employ his own counsel in such Proceeding but the fees and
expenses of such counsel incurred after notice from the corporation of its
assumption of the defense shall be at the expense of the Covered Person unless
(i) the employment of counsel by the Covered Person has been authorized by the
corporation, (ii) the Covered Person shall have concluded reasonably that there
may be a conflict of interest between the corporation and the Covered Person in
the conduct of the defense of such action and such conclusion is confirmed in
writing by the corporation's outside counsel regularly employed by it in
connection with corporate matters, or (iii) the corporation shall not in fact
have employed counsel to assume the defense of such Proceeding, in each of which
cases the fees and expenses of counsel shall be at the expense of the
corporation. The corporation shall not be entitled to assume the defense of any
Proceeding brought by or in the right of the corporation or as to which the
Covered Person shall have made the conclusion provided for in (ii) above and
such conclusion shall have been so confirmed by the corporation's said outside
counsel.
(c) Notwithstanding any provision of this Article to the contrary, the corporation shall not be liable to indemnify the Covered Person under this Article for any amounts paid in settlement of any Proceeding or claim effected without its written consent. The corporation shall not settle any Proceeding or claim in any manner which would impose any penalty, limitation or disqualification of the Covered Person for any purpose without such Covered Person's written consent. Neither the corporation nor the Covered Person will unreasonably withhold their consent to any proposed settlement.
(d) If it is determined that the Covered Person is entitled to
indemnification not covered by defense of the claim afforded under subparagraph
(b) above, payment to the Covered Person of the additional amounts to be
indemnified shall be made within ten (10) days after determination.
(a) the validity, legality and enforceability of the remaining provisions of this Article (including without limitation, each portion of any Section of this Article containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby; and
(b) to the fullest extent possible, the provisions of this Article (including, without limitation, each portion of any Section of this Article containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.
thereof or for using the same for a purpose other than in the interest of the applicant, as a stockholder, relative to the affairs of the corporation.
(a) changes the stockholder voting requirements for any action;
(b) alters or abolishes any preferential right or right of redemption applicable to a class or series of stock with shares already outstanding;
(c) alters the provisions of this Article IX hereof; or
(d) permits the board of directors to take any action which under law, the Certificate of Incorporation, or these By-laws is required to be taken by the stockholders.
Any amendment of these By-laws by the board of directors may be altered or repealed by the stockholders at any annual or special meeting of stockholders.
ABIOMED, INC.
1989 NON-QUALIFIED STOCK OPTION PLAN
FOR NON-EMPLOYEE DIRECTORS
As Amended July 2, 1990 ,August 17, 1992 and June 15, 1995
"Corporation" means ABIOMED, Inc.
"Fair Market Value" means the last sale price of the Shares as reported on the American Stock Exchange or such other national securities exchange or the National Association of Securities Dealers Automated Quotation System ("NASDAQ") on which the Shares may be traded on the date of the granting of the Option or if that day is not a business day on the last business date preceding the date of grant.
"Option" means the contractual right to purchase Shares upon the specific terms set forth in this Plan.
"Option Exercise Period" means the period commencing on the date of grant of an Option pursuant to this Plan and ending ten years from the date of grant.
"Plan" means this ABIOMED, Inc. 1989 Non-Qualified Stock Option Plan for Non-Employee Directors.
"Shares" means the Common Stock, $.01 par value, of the Corporation.
Plan, grant options under the Plan and shall have the power to construe the Plan, to determine all questions as to eligibility, and to adopt and amend such rules and regulations for the administration of the Plan as it may deem desirable. The Board may delegate any and all of its authority hereunder to one or more Committees of the Board.
(a) Subject to the right of the Corporation to accelerate the date on which all or any portion of the Option becomes exercisable and to the provisions of subsection (b) below, each Option holder's right to exercise any Option granted hereunder shall vest in five equal cumulative installments of twenty (20%) percent of the number of shares subject to the Option each, commencing on the June 30 following the date of grant with an additional twenty (20%) percent vesting each successive June 30 thereafter. Notwithstanding any provision of this Agreement to the contrary, in no event may the Option be exercised after ten years from the date of this Agreement (the "Expiration Date").
(b) If one of the events referred to in clauses (i) and (ii) of Paragraph 6(c) occurs, the Option shall be exercisable during the specified period following said permanent disability or death only as to the number of Shares as to which it was exercisable immediately prior to said permanent disability or death.
(c) The purchase price of Shares upon exercise of an Option shall be
paid by the Option holder in full upon exercise and may be paid (i) in cash,
(ii) by delivery of Shares having a Fair Market Value on the date of exercise
equal to the purchase price, or (iii) any combination of cash and Shares, as the
Board may determine.
(d) No Shares shall be issued or transferred upon exercise of any Option under this Plan unless and until all legal requirements applicable to the issuance or transfer of such shares and such other requirements as are consistent with the Plan have been complied with to the satisfaction of the Board, including without limitation those described in Paragraph 10 hereof.
(a) If the Corporation is a party to any merger or consolidation, any purchase or acquisition of property or stock, or any separation, reorganization or liquidation, the Board (or, if the Corporation is not the surviving corporation, the Board of Directors of the surviving corporation) shall have the power to make arrangements, which shall be binding upon the holders of unexpired Options, for the substitution of new options for, or the assumption by another corporation of, any unexpired Options then outstanding hereunder.
(b) If by reason of recapitalization, reclassification, stock split- up, combination of shares, separation (including a spin-off) or dividend on the Stock payable in Shares, the outstanding Shares of the Corporation are increased or decreased or changed into or exchanged for a different number or kind of shares or other securities of the Corporation, the Board shall conclusively determine the appropriate adjustment in the exercise prices of outstanding Options and in the number and kind of shares as to which outstanding Options shall be exercisable.
(c) In the event of a transaction of the type described in Paragraphs
(a) and (b) above, the total number of Shares on which Options may be granted
under this Plan shall be appropriately adjusted by the Board.
holder any right to continue to be affiliated with the Corporation, (ii) giving any Option holder any equity or interest of any kind in any assets of the Corporation, or (iii) creating a trust of any kind or a fiduciary relationship of any kind between the Corporation and any such person. No Option holder shall have any of the rights of a stockholder with respect to Shares covered by an Option until such time as the Option has been exercised and Shares have been issued to such person.
(a) The effective date of this Plan is September 6, 1989. The effective date of any amendment of this Plan shall be the date such amendment is adopted by the Board of Directors, subject to stockholder approval if required under subsection (b).
(b) The Board, or any Committee who has been delegated the authority to do so, may at any time, and from time to time, amend, suspend or terminate this Plan in whole or in part. Provided however, that so long as there is a requirement under Rule 16b-3 under the Securities Exchange Act of 1934, as amended, for stockholder approval of a Plan and certain amendments thereto, any such amendment which (i) materially increases the number of Shares which may be subject to Options granted under the Plan, (ii) materially increases the benefits accruing to participants in the Plan, or (iii) materially modifies the requirement for eligibility to
participate in the Plan, shall be subject to stockholder approval, to the extent so required under said Rule; and provided further that the Plan may not be modified more often than once every six months to materially modify (i) the requirements for eligibility under the Plan, (ii) the timing of the grants of Options under the Plan, (iii) the number of Shares subject to Options to be granted under the Plan, or (iv) the formula for determining the fair market value, other than to comport with changes in the Internal Revenue Code, the Employee Retirement Income Security Act, or the rules thereunder. Except as provided herein, no amendment, suspension or termination of this Plan may adversely affect the rights of any person under an Option that has been granted to such person without such person's consent.
(c) This Plan shall terminate ten years from its effective date, and no Option shall be granted under this Plan thereafter, but such termination shall not affect the validity of Options granted prior to the date of termination.
Date of Board of Director Adoption: July 10, 1989 as amended on July 2, 1990, August 17, 1992 and June 15, 1995.
WHEREAS, the Stockholders and Directors of ABIOMED, Inc. (the "Corporation") approved (A) the Incentive Stock Option Plan, as amended and restated on June 22, 1988 and further amended by Amendment No. 1 and Amendment No. 2 thereto (the "Original Incentive Stock Option Plan"), and (B) the Non- Qualified Stock Option Plan, as amended and restated June 22, 1988 and further amended by Amendment No. 1, Amendment No. 2 and Amendment No. 3 thereto (the "Original Non-Qualified Stock Option Plan") for the purpose of issuing stock options to purchase the Corporation's stock; and
WHEREAS, pursuant to the Original Incentive Stock Option Plan and the Original Non-Qualified Plan (collectively, the "Original Plans"), the Board of Directors now desire to combine and amend and restate the Original Plans as set forth herein;
NOW THEREFORE, the Corporation hereby combines and amends and restates the Original Plans to be in the form of this 1992 Combination Stock Option Plan (hereafter, the term "1992 Plan" includes both this amended and restated plan and each of the Original Plans, as adopted and originally amended, as applicable).
The purposes of the 1992 Plan are (i) to provide long-term incentives and rewards to those employees (the "Employee Participants") of ABIOMED, Inc. (the "Corporation") and its subsidiaries (if any), and any other persons (the "Non- employee Participants") who are in a position to contribute to the long-term success and growth of the Corporation and its subsidiaries, (ii) to assist the Corporation in retaining and attracting executives and employees with requisite experience and ability, and (iii) to associate more closely the interests of such executives and key employees with those of the Corporation's stockholders. Notwithstanding the foregoing, a Director of the Corporation who either (i) is not an employee of the Corporation or (ii) is, or within the past year was, a member of a committee designated by the Board of Directors of the Corporation to administer the 1992 Plan shall not be eligible to receive any options under the 1992 Plan, and shall not be included in the definition of "Non-employee Participants" or "Employee Participants".
Participants to whom Stock Options shall be granted under this 1992 Plan; (iii) determine the size and the form of the Stock Options, if any, to be granted to any Participant; (iv) determine the time or times such Stock Options shall be granted including the grant of Stock Options in connection with other awards made, or compensation paid, to the Participant; (v) establish the terms and conditions upon which such Stock Options may be exercised and/or transferred, including the exercise of Stock Options in connection with other awards made, or compensation paid, to the Participant; (vi) make or alter any restrictions and conditions upon such Stock Options and the Stock received on exercise thereof, including, but not limited to, providing for limitations on the Participant's right to keep any Stock received on termination of employment; and (vii) adopt such rules and regulations, establish, define and/or interpret these and any other terms and conditions, and make all determinations (which may be on a case- by-case basis) deemed necessary or desirable for the administration of this 1992 Plan. Notwithstanding any provision of this 1992 Plan to the contrary, only Employee Participants shall be eligible to receive 1992 Plan ISOs.
of Common Stock (valued at their Fair Market Value on the date of such exercise), (iii) any other property (valued at its Fair Market Value on the date of such exercise), or (iv) any combination of cash, stock and other property, with any payment made pursuant to subparagraphs (ii), (iii) or (iv) only as permitted by the Committee, in its sole discretion. In no event will the purchase price of Common Stock be less than the par value of the Common Stock. Furthermore the purchase price of Common Stock subject to a 1992 Plan ISO shall not be less than the Fair Market Value of the Common Stock on the date of the issuance of the 1992 Plan ISO, provided that in the case of 1992 Plan ISOs granted to Ten Percent Stockholders, the purchase price shall not be less than 110% of the Fair Market Value of the Common Stock on the date of issuance of the 1992 Plan ISO.
state securities laws. The Corporation, in its discretion, may postpone the issuance and delivery of Stock upon any exercise of this Option until completion of such registration or other qualification of such shares under any federal or state laws, or stock exchange listing, as the Corporation may consider appropriate. Furthermore, the Corporation is not obligated to register or qualify the shares of Common Stock to be issued upon exercise of a Stock Option under federal or state securities laws (or to register or qualify them at any time thereafter), and it may refuse to issue such shares if, in its sole discretion, registration or exemption from registration is not practical or available. The Corporation may require that prior to the issuance or transfer of Stock upon exercise of a Stock Option, the Participant enter into a written agreement to comply with any restrictions on subsequent disposition that the Corporation deems necessary or advisable under any applicable federal and state securities laws. Certificates of Stock issued hereunder may bear a legend reflecting such restrictions.
number of shares of Common Stock reserved for purposes of this 1992 Plan, extend the term of this 1992 Plan, materially modify the requirements to be a Participant in this 1992 Plan, or otherwise modify the Plan in any way or manner requiring the approval of the Stockholders under the Code or Section 16 of the 1934 Act, if applicable to the Corporation, or rules and regulations thereunder, without Stockholder Approval and compliance with any applicable law, rules, or regulations. Except as provided herein, no amendment, suspension or termination of this 1992 Plan may affect the rights of a Participant to whom a Stock Option has been granted without such Participant's consent.
The number of shares of Common Stock that may be the subject of awards
under this 1992 Plan shall not exceed an aggregate of 1,300,000 shares,
including shares of Common Stock that were the subject of awards under the
Original Incentive Stock Option Plan and the Original Non-Qualified Stock Option
Plan. Shares to be delivered under this 1992 Plan may be either authorized but
unissued shares of Common Stock or treasury shares. Any shares subject to an
Option hereunder which for any reason terminates, is cancelled or otherwise
expires unexercised, shall, at such time, no longer count towards the aggregate
number of shares which have been the subject of Stock Options issued hereunder,
and such number of shares shall be subject to further awards under this 1992
Plan, provided the total number of shares then eligible for award under this
1992 Plan may not exceed the total specified in the first sentence of this
Section VI.
Provided there is Stockholder Approval on or before December 31, 1992, the effective date of this 1992 Plan is May 1, 1992 (the "Effective Date") and awards under this 1992 Plan may be made for a period of ten years commencing on the Effective Date. The period during which a Stock Option may be exercised may extend beyond that time as provided herein.
ARTICLE 5 |
PERIOD TYPE | 3 MOS | 6 MOS |
FISCAL YEAR END | MAR 31 1996 | MAR 31 1996 |
PERIOD START | JUL 01 1995 | APR 01 1995 |
PERIOD END | SEP 30 1995 | SEP 30 1995 |
CASH | 333,775 | 333,775 |
SECURITIES | 9,483,593 | 9,483,593 |
RECEIVABLES | 2,440,415 | 2,440,415 |
ALLOWANCES | (99,644) | (99,644) |
INVENTORY | 1,253,351 | 1,253,351 |
CURRENT ASSETS | 13,651,344 | 13,651,344 |
PP&E | 2,691,713 | 2,691,713 |
DEPRECIATION | 2,218,449 | 2,218,449 |
TOTAL ASSETS | 15,485,606 | 15,485,606 |
CURRENT LIABILITIES | 1,931,891 | 1,931,891 |
BONDS | 0 | 0 |
COMMON | 69,418 | 69,418 |
PREFERRED MANDATORY | 0 | 0 |
PREFERRED | 0 | 0 |
OTHER SE | 13,484,297 | 13,484,297 |
TOTAL LIABILITY AND EQUITY | 15,485,606 | 15,485,606 |
SALES | 3,106,599 | 5,850,089 |
TOTAL REVENUES | 3,106,599 | 5,850,089 |
CGS | 1,768,054 | 3,341,806 |
TOTAL COSTS | 1,768,054 | 3,341,806 |
OTHER EXPENSES | 1,414,585 | 2,631,499 |
LOSS PROVISION | 0 | 0 |
INTEREST EXPENSE | 124,488 | 255,725 |
INCOME PRETAX | 48,448 | 132,509 |
INCOME TAX | 0 | 0 |
INCOME CONTINUING | 48,448 | 132,509 |
DISCONTINUED | 0 | 0 |
EXTRAORDINARY | 0 | 0 |
CHANGES | 0 | 0 |
NET INCOME | 48,448 | 132,509 |
EPS PRIMARY | .007 | .019 |
EPS DILUTED | .007 | .019 |